LGVN Key Statistics, Chart & Performance
The current stock price of LGVN is 0.506 USD. In the past month the price decreased by -21.43%. In the past year, price decreased by -73.51%.
LGVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About LGVN
Company Profile
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Company Info
LONGEVERON INC-A
1951 NW 7th Ave, Ste 520
Miami FLORIDA 33136 US
CEO: Geoff Green
Employees: 25
Phone: 13053027158
LONGEVERON INC-A / LGVN FAQ
What does LONGEVERON INC-A do?
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Can you provide the latest stock price for LONGEVERON INC-A?
The current stock price of LGVN is 0.506 USD. The price increased by 0.58% in the last trading session.
Does LONGEVERON INC-A pay dividends?
LGVN does not pay a dividend.
How is the ChartMill rating for LONGEVERON INC-A?
LGVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for LONGEVERON INC-A?
LONGEVERON INC-A (LGVN) currently has 25 employees.
What is the ownership structure of LONGEVERON INC-A (LGVN)?
You can find the ownership structure of LONGEVERON INC-A (LGVN) on the Ownership tab.
What is the outstanding short interest for LONGEVERON INC-A?
The outstanding short interest for LONGEVERON INC-A (LGVN) is 7.91% of its float.
LGVN Technical Analysis
LGVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LGVN. While LGVN seems to be doing ok healthwise, there are quite some concerns on its profitability.
LGVN Financial Highlights
Over the last trailing twelve months LGVN reported a non-GAAP Earnings per Share(EPS) of -1.49. The EPS increased by 76.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.18% | ||
| ROE | -214.14% | ||
| Debt/Equity | 0 |
LGVN Forecast & Estimates
9 analysts have analysed LGVN and the average price target is 7 USD. This implies a price increase of 1283.35% is expected in the next year compared to the current price of 0.506.
For the next year, analysts expect an EPS growth of 64.14% and a revenue growth -47.8% for LGVN